HLX42

HLX42 is a novel antibody-drug conjugate (ADC) designed to target the epidermal growth factor receptor (EGFR), a tumor-associated antigen frequently overexpressed or mutated in various solid tumors. The drug consists of a high-affinity humanized IgG1 monoclonal antibody directed against EGFR, conjugated via a cleavable linker to a novel DNA topoisomerase I inhibitor payload. Upon intravenous administration, the linker-payload is cleaved and released specifically within the tumor microenvironment, resulting in strong bystander killing effects and enhanced therapeutic index. The cytotoxic payload induces double-strand DNA breaks and blocks replication machinery, leading to cancer cell apoptosis. Preclinical studies have demonstrated potent anti-tumor activity in models resistant to existing EGFR-targeted therapies such as tyrosine kinase inhibitors (TKIs) and cetuximab. HLX42 is being developed primarily for advanced or metastatic solid tumors—including non-small cell lung cancer (NSCLC), hepatocellular carcinoma, and other EGFR-driven cancers—by Shanghai Henlius Biotech[1][2][3][4][5][6][7].

Other names

YL-221YL221YL 221